Supplementary Table S3 from NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer

X. Cynthia, Matthew J. Ellis(University of California, Davis), Rama Suresh(Washington University in St. Louis), Feng Gao(Washington University in St. Louis), Matthew P. Goetz(Mayo Clinic), Jeremy Hoog(Washington University in St. Louis), Helen Krontiras(University of Alabama at Birmingham), Shana Thomas, Michelle V. Lee, Hussam Al‐Kateb(Washington University in St. Louis), Timothy J. Eberlein, Malachi Griffith(Washington University in St. Louis), Jingqin Luo(Washington University in St. Louis), Andres Forero(University of Alabama at Birmingham), Cynthia Huang Bartlett(Pfizer (United States)), Karen S. Anderson(Arizona State University), María Koehler(Pfizer (United States)), Donald W. Northfelt(Mayo Clinic in Arizona), Zachary L. Skidmore(James S. McDonnell Foundation), Julie A. Margenthaler(Washington University in St. Louis), Rebecca Aft(Washington University in St. Louis), Caroline Bumb(Washington University in St. Louis), Nicholas C. Spies(James S. McDonnell Foundation), Foluso O. Ademuyiwa(Washington University in St. Louis), Timothy J. Moynihan(Mayo Clinic), Tina J. Hieken(Mayo Clinic), William E. Gillanders(Washington University in St. Louis), Souzan Sanati(Washington University in St. Louis), Timothy J. Hobday(Mayo Clinic), Michael Naughton(Boston College), Amy Cyr, Kiran Vij(Washington University in St. Louis), Zhanfang Guo(Washington University in St. Louis), Obi L. Griffith(Washington University in St. Louis)

Unknown

March 31, 2023

Cited by 0

|New England Journal of Medicine|2017|3.2k

|Nature|2012|2k

|The Lancet Oncology|2016|1.8k

|Journal of the National Comprehensive Cancer Network|2018|1.6k

|New England Journal of Medicine|2015|1.6k

Related Papers